Splenosis refers to the heterotropic autotransplantation of splenic tissue. Sometimes splenosis after surgical resection is difficult to differentiate from recurrence or metastasis of cancer. A 49-year-old male patient was diagnosed with clear cell renal cell carcinoma of left kidney. As there was no evidence of metastasis, he underwent radical nephrectomy with splenectomy. On surveillance computed tomography, masses at nephrectomy site and pleura were found and both were initially considered to be recurrence. After several cycle of pazopanib administration, pleural mass decreased in size while mass at nephrectomy site did not respond at all. Spleen scan showed increased uptake of the mass and therefore the mass was revealed to be splenosis. To avoid unnecessary treatment and planning optimal treatment, considering the possibility of splenosis is important and spleen scan can be helpful. (Korean J Urol Oncol 2016;14:176-180)
Splenosis is the dissemination of splenic cells when the capsule integrity of spleen is breached after trauma or removal of spleen. 1 It can be found anywhere accessible to the splenic tissue. Reported sites of splenosis after splenectomy are surgical bed of the removed spleen, liver, peritoneal cavity, retroperitoneum, pelvis, and mediastinum. 2, 3 This lesion is sometimes difficult to differentiate from recurrence or metastasis of cancer especially when splenosis develops after curative intent of cancer surgery including splenectomy. 4 Furthermore, if splenosis or accesory spleen is mistaken for recurrent cancer, patients can undergo unnecessary treatment. 5 Here we report on a case of a patient with renal cell carcinoma (RCC) whose accessory spleen on the nephrectomy site was midguided as recurrence of cancer.
CASE REPORT
A 49-year-old male patient came to the clinic complaining of abdominal discomfort. His computed tomography (CT) scan revealed 6-cm-sized left renal mass involving upper-mid pole which invaded perirenal fat but not not beyond Gerota's fascia.
Lymph node enlargement or distant metastasis was not detected H&E, x200; C: H&E, x400). On CT imaging taken 3 months after pazopanib, the lung lesion had decreased in size (2.2 cm → 1.0 cm) while the mass on the nephrectomy site showed no change in size or enhancement. After 6 months after the start of pazopanib, the lung lesion continued to decrease in size while the mass on the nephrectomy site became slightly increased (2.7 cm → 3.0 cm) (Fig. 4) .
A spleen scan ( 99m Tc heat-damaged red blood cell [RBC] scan) was performed to determine the reason for discordant response between lung and nephrectomy site lesions. A soft tissue lesion at the nephrectomy surgical bed showed increased up- . Spleen scan showed increased uptake in the soft tissue lesion at the left nephrectomy site (arrow), which was found to be splenosis.
take, indicating that the mass was a splenosis (Fig. 5) . Because his lung metastasis responded well, pazopanib was continued.
He is alive without disease progression as of January 2016.
DISCUSSION
Surgical resection can be curative for localized RCC, but, unfortunately, some patients experience recurrence after surgery. In the current case, it was difficult to differentiate recurrence of RCC from splenosis because there was concurrent lung recurrence on CT scan and PET-CT scan showed increased FDG uptake in both lung and splenosis lesions. Among most published cases, splenosis is reported to exhibit normometabolic FDG-PET activity. However, splenosis can present with increased FDG-PET uptake. 7 Therefore, the extent of FDG-PET uptake cannot be used as an absolute criterion for deciding whether a mass near splenectomy site is a malignant lesion or not. As shown on the spleen scan, the lung lesion was true metastasis while the lesion on the nephrectomy site was not.
Splenic scintigraphic scan using Tc-labeled heat-damaged RBC, which was utilized in our case, provides better specificity and sensitivity in splenectomized patients. Because heat-damaged RBC fragments are larger in size than 99m Tc-sulfur colloid materials(0.3 to 1.0 m), the spleen traps upto 90% of injected damaged RBCs, whereas it traps only about 10% of injected Sulfur colloid. 9 Sensitivity and specificity of splenic scintigraphic scan for detecting splenosis after splenectomy is not known, but referring the study of Ekmekçi et al., 10 there was no false positive finding in splenic scintigraphy using 99m Tc-labeled heat-damaged RBC in the detection of accessory spleens/splenosis in both splenectomized and nonsplenectomized patients. Spleen scan can be economical and very specific in this setting, as previously reported.
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We did not consider metastasectomy at initial presentation of recurrence because it appeared to be multiple metastases in separate organs and interval from nephrectomy to recurrence was relatively short (4 months). If we determined that the mass in the nephrectomy surgical bed was accessory spleen, we could strongly consider metastasectomy for the lung lesion instead of systemic treatment which was toxic to the patient.
To avoid futile toxic treatment and for planning of optimal management, awareness of the possibility of accessary spleen is important to both surgical and medical oncologist when a left abdominal mass is discovered after surgery including splenectomy. In addition, spleen scan can be helpful in dis-tinguishing splenosis after surgical treatment from recurrence.
